logo-loader
viewProactive Australia

Kyckr Ltd lists on the ASX, develops unique corporate identity service

au_asx358_57cfabec22677.jpg

Kyckr Ltd (ASX:KYK) commenced trading today after a successful IPO raising circa $5 million through the issue of shares priced at $0.20.

Kyckr provides ‘Know Your Business’ (KYB) compliance services to clients in any sector that is open to fraud and money laundering, by providing corporate data in exchange for a subscription fee.

The company’s network of corporate data includes 70 million legal entities from 150 business registries around the world.

Kyckr is looking to benefit from the tightening of anti-money-laundering and counter-terrorism financing regulations across the world.

The company has also developed a corporate identity blockchain capability that will accompany Kyckr’s commercially proven automation model for KYB.

Blockchain technology, which incorporates unique identifiers for each financial transaction, is expected to enhance Kyckr’s service offering.

Kyckr had announced unaudited revenue of $1.2 million for FY2016, a 124% increase over FY2015 revenue of $542,735.

The global compliance market is estimated to be worth US$70 billion - US$80 billion.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Proactive Australia

Price: - -

ASX:.
Market: ASX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings raises over a £1mln to advance preclinical work on its...

Sareum Holdings PLC's (LON:SAR) Tim Mitchell caught up with Proactive London's Andrew Scott following the news it's raised just over £1mln to advance the preclinincal work on its TYK2/JAK1 drugs SDC-1801 and SDC-1802. Mitchell says they're exploring the potential benefit of the TYK2/JAK1...

38 minutes ago

2 min read